- Home
- BIRK vs PCVX Comparison
BIRK vs PCVX Comparison
Compare BIRK & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BIRK | PCVX |
|---|---|---|
| Founded | 1774 | 2013 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.1B |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BIRK | PCVX |
|---|---|---|
| Price | $34.10 | $54.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 7 |
| Target Price | $62.69 | ★ $98.33 |
| AVG Volume (30 Days) | ★ 2.1M | 1.1M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.71 | N/A |
| Revenue Next Year | $14.21 | N/A |
| P/E Ratio | $17.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.06 | $28.09 |
| 52 Week High | $57.39 | $65.00 |
Technical Indicators
Market Signals| Indicator | BIRK | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 37.09 | 46.90 |
| Support Level | $33.06 | $42.30 |
| Resistance Level | $42.19 | $56.04 |
| Average True Range (ATR) | 1.58 | 2.27 |
| MACD | -0.21 | -0.35 |
| Stochastic Oscillator | 17.21 | 39.05 |
Price Performance
Historical ComparisonAbout BIRK Birkenstock Holding plc
Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.